10390
Pacific Center Court, San Diego, CA 92121-4340
858·646·1100,
FAX: 858·646·1150
www.vical.com
|
News
Release
|
Alan
R. Engbring
|
Jill
M. Church
|
|
Executive
Director, Investor Relations
|
Vice
President and Chief Financial Officer
|
|
(858)
646-1127
|
||
Website:
www.vical.com
|
·
|
New
mouse data with Vaxfectin®-formulated
seasonal influenza vaccines demonstrating the ability to adjust the
ratio
of Vaxfectin®
to
vaccine and drive substantial increases in either antibody or T-cell
responses, without reducing the other type of response, compared
with
unformulated vaccine;
|
·
|
A
mouse study demonstrating a 100-fold increase in antigen-specific
CD8+
T-cell responses with a Vaxfectin®-formulated
cancer vaccine compared with unformulated
vaccine;
|
·
|
A
research collaboration with the Karolinska Institutet and the Swedish
Institute for Infectious Disease Control to evaluate a
Vaxfectin®-formulated
preventive DNA vaccine against HIV in a Phase 1 human clinical trial
as
part of a prime-boost regimen; and
|
·
|
Publication
in the August issue of “Clinical and Vaccine Immunology” of results
demonstrating long-term protection against measles challenge in juvenile
and infant nonhuman primates with a Vaxfectin®-formulated
DNA vaccine.
|
Statements of Operations |
Three
Months Ended Sept. 30,
|
Nine
Months Ended Sept. 30,
|
|||||||||||
(in
thousands, except per share amounts)
|
2008
|
2007
|
2008
|
2007
|
|||||||||
Revenues:
|
|||||||||||||
Contract
and grant revenue
|
$
|
711
|
$
|
164
|
$
|
1,604
|
$
|
3,994
|
|||||
License
and royalty revenue
|
133
|
211
|
3,727
|
747
|
|||||||||
Total
revenues
|
844
|
375
|
5,331
|
4,741
|
|||||||||
Operating
expenses:
|
|||||||||||||
Research
and development
|
6,226
|
5,580
|
19,284
|
17,314
|
|||||||||
Manufacturing
and production
|
2,716
|
2,871
|
8,772
|
11,034
|
|||||||||
General
and administrative
|
2,087
|
2,192
|
6,439
|
6,825
|
|||||||||
Total
operating expenses
|
11,029
|
10,643
|
34,495
|
35,173
|
|||||||||
Loss
from operations
|
(10,185
|
)
|
(10,268
|
)
|
(29,164
|
)
|
(30,432
|
)
|
|||||
Net
investment income
|
360
|
1,029
|
1,292
|
3,399
|
|||||||||
Net
loss
|
$
|
(9,825
|
)
|
$
|
(9,239
|
)
|
$
|
(27,872
|
)
|
$
|
(27,033
|
)
|
|
Basic
and diluted net loss per share
|
$
|
(0.24
|
)
|
$
|
(0.24
|
)
|
$
|
(0.70
|
)
|
$
|
(0.69
|
)
|
|
Weighted
average shares used to calculate basic and diluted net loss per
share
|
40,349
|
39,193
|
39,688
|
39,189
|
Balance Sheets |
September
30,
|
December
31,
|
|||||
(in
thousands)
|
2008
|
2007
|
|||||
Assets:
|
|||||||
Cash,
cash equivalents, and marketable securities
|
$
|
43,022
|
$
|
71,489
|
|||
Other
current assets
|
1,649
|
1,2617
|
|||||
Total
current assets
|
44,671
|
2,750
|
|||||
Marketable
securities
|
6,000
|
-
|
|||||
Property
and equipment, net
|
11,146
|
12,287
|
|||||
Other
assets
|
4,948
|
5,548
|
|||||
Total
assets
|
$
|
66,765
|
$
|
90,585
|
|||
Liabilities
and stockholders' equity:
|
|||||||
Current
liabilities
|
$
|
7,522
|
$
|
8,108
|
|||
Long-term
obligations
|
2,480
|
2,565
|
|||||
Stockholders'
equity
|
56,763
|
79,912
|
|||||
Total
liabilities and stockholders' equity
|
$
|
66,765
|
$
|
90,585
|